Trypanothione reductase (Trypanosoma brucei) (TbTR)

Trypanothione reductase (TR) is a vital flavoenzyme found in Trypanosoma brucei, the causative agent of Human African Trypanosomiasis (sleeping sickness) [1.1.1, 1.3.1]. It plays a central role in the parasite's unique antioxidant defense system by catalyzing the NADPH-dependent reduction of trypanothione disulfide into reduced trypanothione [1.3.2, 1.3.5]. This process is essential for maintaining intracellular redox homeostasis and protecting the parasite from oxidative damage caused by reactive oxygen species (ROS) generated by the host's immune response [1.1.1, 1.4.4]. Unlike its mammalian hosts, which rely on the glutathione/glutathione reductase system, trypanosomatids depend entirely on the trypanothione system, making TR an exceptionally attractive target for selective drug development [1.1.1, 1.3.3]. Inhibition of TR leads to a lethal accumulation of oxidative stress within the parasite [1.3.1, 1.4.4]. While several experimental inhibitors such as quinolines and gold-based compounds like auranofin have shown promise, the development of potent, drug-like inhibitors remains a challenge due to the enzyme's large and relatively featureless active site [1.4.1, 1.4.3].

Other names

Trypanothione-disulfide reductaseNADPH:trypanothione oxidoreductaseN(1),N(8)-bis(glutathionyl)spermidine reductaseTryR

Inhibition of the enzyme prevents the reduction of trypanothione disulfide to reduced trypanothione, resulting in the accumulation of reactive oxygen species and subsequent parasite death [1.1.1, 1.3.1].